Skip to main content
search

Late Clinical

Sign up

Latest resources

Featured resource

Upcoming late clinical webinars

Latest late clinical blogs

Meet our experts at the following events

Conference

Fierce BIO

January 13 - 14, 2026 – Hyatt Regency San Francisco, CA
Conference

ICoP 2026 India

January 28 - 31, 2026
Conference

DIA RSIDM 2026

February 2 - 4, 2026 – Bethesda North Marriott Hotel & Conference Center, North Bethesda, MD – Booth 202

All late clinical resources

Population Pharmacokinetics of Vernakalant Hydrochloride Injection (RSD1235) in Patients with Atrial Fibrillation or Atrial Flutter

Cardiovascular, Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Therapeutic Specialties, Publication

Modeling and Simulation of Edoxaban Exposure and Response Relationships in Patients with Atrial Fibrillation

Cardiovascular, Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Therapeutic Specialties, Publication

Placebo Response Changes Depending on the Neuropathic Pain Syndrome: Results of a Systematic Review and Meta-analysis

Central Nervous System (CNS), Certara Services, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation - PK/PD, pre-update, Therapeutic Specialties, Publication

Physiologically-based PharmacoKinetic (PBPK) Modeling Tools: How to Fit with Our Needs?

Certara Products - Simcyp, Modeling and Simulation - PBPK, pre-update, Publication

Mechanism-based Population Modeling of the Effects of Vildagliptin on GLP-1, Glucose, and Insulin in Patients with Type 2 Diabetes

Model Informed Drug Development, pre-update, Publication

Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites

Endocrinology, Model Informed Drug Development, Modeling and Simulation - PK/PD, pre-update, Therapeutic Specialties, Publication

Physiologically-based Pharmacokinetic (PBPK) Modeling: It is Here to Stay!

Model Informed Drug Development, pre-update, Publication

Application of PBPK Modeling in Drug Discovery and Development at Pfizer

Model Informed Drug Development, pre-update, Publication

Exposure-response Relationship of AMG 386 in Combination with Weekly Paclitaxel in Recurrent Ovarian Cancer and Its Implication for Dose Selection

Model Informed Drug Development, Modeling and Simulation - PK/PD, Oncology/Hematology, pre-update, Therapeutic Specialties, Publication

Model-based Meta-analysis for Comparative Efficacy and Safety: Application in Drug Development and Beyond

Certara Services, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), pre-update, Publication

Therapeutic Index of Anticoagulants for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-response Meta-analysis

Cardiovascular, Certara Services, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation - PK/PD, Oncology/Hematology, pre-update, Therapeutic Specialties, Publication

A Dose-response Meta-analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid Arthritis

Certara Services, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation - PK/PD, pre-update, Publication
Sign up to newsletter

Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.